Drug Target Review
OCTOBER 16, 2023
This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response. Nikki drives adoption of 3D cellular models of human disease by applying her expertise in cell biology to drug discovery and high-throughput screening.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 3, 2021
About NexImmune NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology. . GAITHERSBURG, Md.,
Broad Institute
MAY 21, 2025
In the 1990s, Michel Sadelain then at Memorial Sloan Kettering Cancer Center (MSKCC) designed CARs by combining fragments of tumor-recognizing antibodies with the molecular machinery found in T-cell receptors. That ability to stick around, which is critical for attacking cancer over time, was another turning point.
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.
Drug Target Review
OCTOBER 2, 2024
While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.
The Pharma Data
DECEMBER 31, 2020
“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.
Expert insights. Personalized for you.
122 
Let's personalize your content